PDS Biotechnology

PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. Versamune® -its novel synthetic nanoparticle platform technology- activates multiple immunological mechanisms which direct the targeting of cancer and infectious disease by the immune system.


In May 2015 PDS announced positive preliminary data showing that its lead cancer immunotherapy treatment, PDS0101, has generated strong T-cell responses in pre-cervical cancer. In February 2016 PDS signed a Cooperative Research and Development Agreement with the National Cancer Institute, a division of the US National Institutes of Health. The goal is to co-develop novel cancer immunotherapies through Phase II clinical trials that will start in 2016 and 2017.

PDS has recently strengthened its senior management team with the recruitment of a Chief Medical Officer and VP of Drug Development and Manufacturing. NetScientific has invested £1.76m for a 14.85% shareholding in PDS.


Therapeutics – Cancer Immunotherapy

Management Team

Frank Bedo-Addo, CEO

Company HQ

North Brunswick, NJ, US



PDS Biotechnology - NetScientific